Clinical classification of BRCA1 and BRCA2 DNA sequence variants: The value of cytokeratin profiles and evolutionary analysis - A report from the kConFab investigators

Journal of Clinical Oncology

Volumn 26, Issue 10, 2008, Pages 1657-1663

  Spurdle, Amanda B ^a   Lakhani, Sunil R ^a   Healey, Sue ^a   Parry, Suzanne ^a   Da Silva, Leonard M ^a   Brinkworth, Ross ^a   Hopper, John L ^a   Brown, Melissa A ^a   Babikyan, Davit ^a   Chenevix Trench, Georgia ^a   Tavtigian, Sean V ^a   Goldgar, David E ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOKERATIN 14; CYTOKERATIN 5; CYTOKERATIN 6; ESTROGEN RECEPTOR; KERATIN; TUMOR MARKER;

ARTICLE; BREAST CANCER; CLINICAL CLASSIFICATION; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE DELETION; GENE MUTATION; GENETIC CONSERVATION; GENETIC COUNSELING; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PATHOGENICITY; PRIORITY JOURNAL; SEGREGATION ANALYSIS; SEQUENCE ALIGNMENT; AMINO ACID SEQUENCE; BIOSYNTHESIS; BREAST TUMOR; EVOLUTION; GENETIC VARIABILITY; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PEDIGREE; STATISTICAL MODEL; TUMOR SUPPRESSOR GENE;

AMINO ACID SEQUENCE; BASE SEQUENCE; BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA MUTATIONAL ANALYSIS; EVOLUTION; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; LIKELIHOOD FUNCTIONS; MOLECULAR SEQUENCE DATA; MUTATION; PEDIGREE; RECEPTORS, ESTROGEN; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL; VARIATION (GENETICS);

EID: 43249105056     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.2779     Document Type: Article

References (25)

1. National Human Genome Research Institute: An open access on-line breast cancer mutation data base. http://research.nhgri.nih.gov/projects/bic
2. Goldgar DE, Easton DF, Deffenbaugh AM, et al: Integrated evaluation of DNA sequence variants of unknown clinical significance: Application to BRCA1 and BRCA2. Am J Hum Genet 75:535-544, 2004
3. Chenevix-Trench G, Healey S, Lakhani S, et al: Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res 66:2019-2027, 2006
4. Foulkes WD, Brunet JS, Stefansson IM, et al: The prognostic implication of the basal-like (cyclinEhigh/p27low/p53+/glomeruloid-microvascular- proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 64:830-835, 2004
5. Foulkes WD, Stefansson IM, Chappuis PO, et al: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:1482-1485, 2003
6. Lakhani SR, Reis-Filho JS, Fulford L, et al: Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11:5175-5180, 2005
7. Rodriguez-Pinilla SM, Sarrio D, Honrado E, et al: Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol 60:1006-1012, 2007
8. Mann GJ, Thorne H, Balleine RL, et al: Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res 8:R12, 2006
9. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al: The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310-2318, 2002
10. Brzovic PS, Meza JE, King MC, et al: BRCA1 RING domain cancer-predisposing mutations: Structural consequences and effects on protein-protein interactions. J Biol Chem 276:41399-41406, 2001
11. Williams RS, Green R, Glover JN: Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nat Struct Biol 8:838-842, 2001
12. Shin DS, Pellegrini L, Daniels DS, et al: Fulllength archaeal Rad51 structure and mutants: Mechanisms for RAD51 assembly and control by BRCA2. Embo J 22:4566-4576, 2003
13. Easton DF, Deffenbaugh AM, Pruss D, et al: A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 81:873-883, 2007
14. Tavtigian SV, Deffenbaugh AM, Yin L, et al: Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 43:295-305, 2006
15. Lakhani SR, Jacquemier J, Sloane JP, et al: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90:1138-1145, 1998
16. Lakhani SR, Gusterson BA, Jacquemier J, et al: The pathology of familial breast cancer: Histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 6:782-789, 2000
17. Thompson D, Easton DF, Goldgar DE: A full-likelihood method for the evaluation of causality of sequence variants from family data. Am J Hum Genet 73:652-655, 2003
18. Lovelock PK, Spurdle AB, Mok M, et al: Pathogenicity of the BRCA1 unclassified sequence variants R1699Q, and A1708V: Assessment using functional assays and multifactorial likelihood analysis. Breast Cancer Res 9:R82, 2007
19. Antoniou A, Pharoah PD, Narod S, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72:1117-1130, 2003
20. Judkins T, Hendrickson BC, Deffenbaugh AM, et al: Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations. Cancer Res 65:10096-10103, 2005
21. Osorio A, Milne RL, Honrado E, et al: Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information. Hum Mutat 28:477-485, 2007
22. Meindl A: Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer 97:472-480, 2002
23. Gayther SA, de Foy KA, Harrington P, et al: The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer: The Cancer Res Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. Cancer Res 60:4513-4518, 2000
24. Peelen T, van Vliet M, Bosch A, et al: Screening for BRCA2 mutations in 81 Dutch breast-ovarian cancer families. Br J Cancer 82:151-156, 2000
25. Wu K, Hinson SR, Ohashi A, et al: Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res 65:417-426, 2005